Gilead Sciences | GILD - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
AbbVie USD 3.63B 54M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
ALKERMES USD 196.64M 67.96M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amgen USD 1.72B 134M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.43B 496M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Incyte USD 351.73M 23.64M 2026-06
J&J USD 6.42B 381M 2026-06
Merck USD 2.89B 219M 2026-06
Moderna USD 216M 43M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.63B 307M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
United Therapeutics USD 206.7M 50.1M 2026-06
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06